{"id":"W2808818020","doi":"10.1093/ecco-jcc/jjy079","title":"Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension","year":2018,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"Janssen Biotech; Janssen Research and Development; Kyowa Hakko Kirin; Genentech; Janssen Scientific Affairs; Biogen; Celgene; Novo Nordisk; Teva Pharmaceutical Industries; Gilead Sciences; Takeda Oncology; Tillotts Pharma; Amgen; Dr. Falk Pharma; Pfizer; Ironwood Pharmaceuticals, Incorporated; Eli Lilly and Company; Bristol-Myers Squibb; ActoGeniX; Sanofi; UCB Pharma; Abbott Laboratories","keywords":"Golimumab; Medicine; Ulcerative colitis; Extension (predicate logic); Term (time); Internal medicine; Gastroenterology; Adalimumab; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001622617,0.0001371364,0.0001990422,0.00002491155,0.0001310014,0.00005154371,0.0001786767,0.00007478884,0.000009775383],"category_scores_gemma":[0.0001809033,0.00009064448,0.0000755963,0.00003928481,0.0001520371,0.00001922059,0.0000672695,0.00006747284,0.000001177211],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002769089,"about_ca_system_score_gemma":0.0001401817,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002722079,"about_ca_topic_score_gemma":0.00037199,"domain_scores_codex":[0.9989851,0.00004874416,0.0003421778,0.0002121538,0.0002115099,0.0002003338],"domain_scores_gemma":[0.997725,0.00005184004,0.0003737253,0.0002059315,0.001505043,0.0001384376],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.954469,0.0004643339,0.004672108,0.00006105535,0.0007427537,0.0001683809,0.00247256,0.00009205601,0.0009613152,0.0005502744,0.01021233,0.02513378],"study_design_scores_gemma":[0.003057084,0.001392129,0.9879917,0.0001798056,0.00005835931,0.00001374229,0.00012645,0.00001592688,0.005839357,0.0003379252,0.0008615259,0.0001259952],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974699,0.00003782295,0.0004758124,0.0001942322,0.0001151494,0.0004258995,0.001066654,0.000001605003,0.0002129205],"genre_scores_gemma":[0.9985653,0.00004699913,0.0004010051,0.000416031,0.0003209481,0.00001385127,0.00004255502,0.00001636118,0.0001769264],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9833196,"threshold_uncertainty_score":0.3696375,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008796704275296016,"score_gpt":0.2409134671581696,"score_spread":0.2321167628828736,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}